Astonea Labs Posts Strong H1 FY27 Growth and Outlines Aggressive Multi-Year Targets
Astonea Labs Ltd · Financial Result · 14 Nov 2026, 11:25 pm
Astonea Labs Posts Strong H1 FY27 Growth and Outlines Aggressive Multi-Year Targets Astonea Labs delivered robust consolidated H1 FY27 performance, with revenue surging 44.6% YoY to ₹95.86 Cr, EBITDA jumping 140.7% YoY to ₹13.20 Cr (margin expanded 550 bps to 13.8%), and PAT rising 153.3% YoY to ₹4.82 Cr. The board approved acquiring a 51% stake in Longevity Science Pvt Ltd. Management guided for FY27 revenue of ₹215+ Cr with a 13–15% EBITDA margin, targeting ₹300+ Cr in FY28 and ₹405+ Cr in FY29 (~40% CAGR from FY26), driven by domestic OTC brands and export expansion.
Original exchange filing (PDF)
More announcements from Astonea Labs Ltd
- Non-Applicability of Statement of Deviation & Variation for the half year ended 30th September, 2026 · 15 Nov 2026
- Revised Outcome of Board Meeting held on 14th November, 2026 · 15 Nov 2026
- Outcome of Board Meeting held on 14th November, 2026 · 14 Nov 2026
- Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated .... · 14 Nov 2026
- Please find enclosed herewith an Intimation regarding change in the Corporate Identification Number (CIN) of the Company consequent upon alteration of the Object Clause of the Memorandum .... · 09 Oct 2026
- Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Incorporation of Proposed Subsidiary- Longevity Science Private Limited · 08 Oct 2026
- Please find enclosed herewith re-submission of financial results for the half year and year ended 31.03.2025. · 22 Sept 2026
- Please find enclosed herewith resubmission of financial results for the financial year ended 31.03.2025, as the same was submitted in XBRL Version and as a part of outcome of the Board .... · 19 Sept 2026
